On October 17, 2025, Palisade Bio, Inc. held its annual meeting where shareholders elected three directors, ratified Baker Tilly US, LLP as auditors, and approved a proposed reverse stock split between 1-for-5 and 1-for-50. Approximately 39.32% of shares were represented at the meeting.